GHK-Cu

Quick Summary

What it is. GHK-Cu — a naturally occurring copper-binding tripeptide (glycyl-L-histidyl-L-lysine) that circulates in human plasma and declines significantly with age.

Most-studied uses. Wound healing, skin rejuvenation, hair regrowth, and anti-aging applications. Strongest cosmetic evidence base of any compound on the April 15 list.

Current U.S. legal status (May 2026). GHK-Cu was removed from FDA Category 1 (not Category 2) on April 15, 2026, because its nominator withdrew the nomination. Unlike the other 11 reclassified peptides, GHK-Cu was previously in an enforcement discretion category. Its PCAC review is scheduled before February 2027, not at the July 2026 meeting. Licensed compounding pharmacies should exercise caution in the interim.

Expected post-PCAC price. $80–$150 per vial at a legitimate compounding pharmacy — typically the most affordable of the reclassified peptides due to simpler manufacturing.

Evidence base. Published placebo-controlled human clinical trials for topical use — unique among the reclassified peptides. Injectable data is limited to preclinical and practitioner evidence.

What is GHK-Cu?

GHK-Cu is a naturally occurring tripeptide — a chain of three amino acids (glycine, histidine, lysine) — that binds copper and circulates in human blood plasma. It was first identified in the 1970s by Dr. Loren Pickart, who discovered that the peptide’s concentration in human plasma declines sharply with age: levels in a 20-year-old are roughly ten times higher than in a 60-year-old Pickart, 2008.

The copper-binding property is functionally critical. GHK-Cu acts as a copper shuttle, delivering the metal ion to enzymes that require it for collagen synthesis, superoxide dismutase activity, and other tissue-repair processes. Without the copper, the tripeptide is inactive.

GHK-Cu occupies a unique position among the 12 reclassified peptides: it is the only one with published placebo-controlled human clinical trial data for topical use, it is the only one whose concentration in the human body is known to decline with age (creating a plausible biological rationale for supplementation), and it has the longest history of safe commercial use in cosmetics — copper peptides have been sold in over-the-counter skin care products for decades.

What the Research Shows

Human clinical data — topical

GHK-Cu has the strongest human clinical evidence base of any compound on the April 15 reclassification list, but with an important limitation: most of the controlled human data is for topical administration, not injectable.

A placebo-controlled clinical study of GHK-Cu applied topically to women aged 50–59 found statistically significant improvements in skin density, skin firmness, and wrinkle depth after 12 weeks of application. A separate controlled study demonstrated improved wound healing rates in surgical incision sites treated with GHK-Cu compared to vehicle alone Pickart et al., 2015.

These findings are not trivial. The placebo-controlled topical data represent a meaningful evidence advantage over essentially every other peptide on the April 15 list, for which such data does not exist.

Preclinical evidence — injectable

Published preclinical research on injectable GHK-Cu shows effects in:

• Collagen synthesis. GHK-Cu stimulates collagen production in fibroblast cultures at concentrations as low as 10^(-12) M, suggesting a genuine signaling role in tissue repair Maquart et al., 1988.
• Wound healing. Multiple rodent wound-healing models show accelerated closure and improved tissue organization with GHK-Cu administration.
• Angiogenesis. The peptide promotes new blood vessel formation in animal models, which is relevant to wound-healing applications.
• Anti-inflammatory effects. GHK-Cu upregulates antioxidant enzyme systems and downregulates pro-inflammatory cytokine expression in cellular models.
• Hair growth. Follicular studies suggest GHK-Cu may support hair follicle vascularization through VEGF upregulation, though controlled human data on hair regrowth is limited.

The gap between topical human data and injectable human data is the key limitation. The cosmetic-grade topical data supports safety and efficacy for skin applications, but the injectable route — which is what compounding pharmacies will supply — relies on the preclinical evidence and practitioner experience, not on controlled injectable human trials.

Where GHK-Cu is most commonly prescribed

In the practitioner community, GHK-Cu is most frequently prescribed for facial skin rejuvenation as an adjunct to microneedling or other cosmetic procedures, generalized anti-aging applications including skin laxity and texture improvement, wound healing and scar reduction, and hair thinning (typically in combination with other agents under practitioner supervision).

Injectable GHK-Cu is also commonly used as a “stacking” component — prescribed alongside BPC-157, TB-500, or other peptides — though combination protocols, like virtually all injectable peptide protocols, lack controlled human comparative data.

Legal and Regulatory Status

GHK-Cu’s unique regulatory position

This is the most important distinction for GHK-Cu. Unlike the other 11 peptides removed from Category 2 on April 15 — which had been designated as “raising significant safety concerns” — GHK-Cu was listed in Category 1, the category for substances under evaluation for which the FDA exercises enforcement discretion.

The nominator withdrew the GHK-Cu nomination, which triggered its removal from Category 1. The FDA formally announced this change on April 15, 2026. The practical difference:

• The 11 Category 2 peptides moved from “presumptively prohibited” to an interim evaluation tier.
• GHK-Cu moved from “enforcement discretion” to the same interim tier — meaning the FDA’s prior enforcement discretion protection no longer applies.

PCAC timeline — early 2027, not July 2026

The July 23–24 PCAC meeting will consider seven peptides: BPC-157, KPV, TB-500, MOTS-c, DSIP, Semax, and Epitalon. GHK-Cu is not on the July agenda. Its PCAC review is scheduled before the end of February 2027 — roughly seven months after the first group.

This delayed timeline has practical consequences. Pharmacies seeking clarity on GHK-Cu’s 503A Bulks List status will not receive it until early 2027. The interim period — April 2026 to early 2027 — is a regulatory gray area for all 12 peptides, but GHK-Cu’s removal from Category 1 means it lacks even the enforcement discretion cover that Category 1 provided.

State-level variance

Same state-level considerations apply as with other reclassified peptides. See the state-by-state tracker for your jurisdiction.

How It’s Typically Administered

GHK-Cu is most commonly administered by subcutaneous injection for systemic effects or topical application for localized skin treatment. Intradermal injection in conjunction with microneedling is a common aesthetic-medicine protocol. Oral GHK-Cu is not considered bioavailable and is not prescribed.

Safety Profile

Reported adverse events from injectable GHK-Cu are rare in the practitioner literature. The most commonly reported issues are injection-site reactions (mild redness, swelling, itching) that resolve within 24–48 hours. No published major safety signals have been identified.

A term that appears in online communities — “copper uglies” — describes anecdotal reports of temporary skin texture worsening when initiating GHK-Cu use. This phenomenon has not been studied in controlled trials and is not well understood. Some practitioners attribute it to a transient inflammatory or remodeling phase. Resolves in most reported cases within 2–4 weeks of continued use.

What It Costs

Expected pricing post-PCAC from legitimate compounding pharmacies:

Form	Expected Price Range
GHK-Cu 50mg vial, injectable	$80–$150
Pre-mixed topical formulation (30ml)	$60–$120
GHK-Cu + BPC-157 combination vial	$150–$250

GHK-Cu is typically the most affordable of the reclassified peptides due to its simpler linear tripeptide structure, lower raw-material cost, and well-characterized manufacturing processes.

Sourcing Framework

Same sourcing rules apply as for every peptide on the April 15 list:

1. Work with a licensed prescriber who is qualified to evaluate whether GHK-Cu is appropriate for your situation.
2. Source through a PCAB-accredited compounding pharmacy, not the research-chemical channel.
3. The gray market is particularly hazardous for GHK-Cu because copper content can be easily adulterated or misrepresented. If the copper-to-peptide ratio is wrong, the product is inactive at best and potentially irritating.
4. Verify your state’s pharmacy board rules — see the state-by-state tracker.
5. Read the 2026 Peptide Law Playbook for the full sourcing and prescriber-conversation framework.

Bottom Line

GHK-Cu is the compound on the April 15 list with the strongest cosmetic evidence base and most unusual regulatory history. The topical human clinical data is a genuine advantage — it is the only reclassified peptide with published placebo-controlled trials — but the injectable evidence gap remains significant, and the delayed PCAC timeline (early 2027) creates a longer regulatory limbo period than any of the 11 Category 2 peptides.

For patients considering GHK-Cu for skin rejuvenation or wound healing: the topical data supports informed clinical judgment. The injectable route should be approached with the same caution applicable to every compound on the reclassification list. For the full landscape on the April 15 action and PCAC process, see the FDA reclassification breakdown and the PCAC meeting preview.

PeptidesBeat is an independent editorial publication covering peptide policy, research, and industry developments. We do not sell peptides, recommend dosing, or provide medical advice. All content is informational. Peptides referenced may be subject to FDA restrictions; consult a licensed healthcare provider for any therapeutic question.